Naveen Pemmaraju/X
Sep 8, 2025, 07:11
Naveen Pemmaraju at SOHO 2025: Presenting Effects of Rusfertide for Polycythemia Vera on Behalf of VERIFY Colleagues
Naveen Pemmaraju, Executive Director-Cancer Medicine for MDACC Cancer Network, shared on X:
”SOHO 2025
Thanks to Society of Hematologic Oncology for the opportunity to present, on behalf of VERIFY colleagues, our randomized phase 3 results hepcidin mimetic Rusfertide for patients with Polycythemia Vera (PV).”
More from SOHO 2025 featured in Hemostasis Today.
-
Nov 16, 2025, 19:46Ayodeji Olayanju: Academics Blood Matter Too!
-
Nov 16, 2025, 19:30Thomas Reiser Congratulates Saskia Middeldorp on Delivering the 2025 Sol Sherry Distinguished Lecture in Thrombosis
-
Nov 15, 2025, 15:47Shannon Farmer: Congratulations to Susan Goobie and Colleagues on Publication of Their Important Study
-
Nov 15, 2025, 15:46Fotios Barkas: Explore the Latest Articles From the Journal of Atherosclerosis Prevention and Treatment!
-
Nov 15, 2025, 15:45Ludovic Helfgott: Researchers Have Analysed Novo Nordisk Product Data in Obesity and Cardiovascular Disease
-
Nov 15, 2025, 15:42Haroun Gajraj Thanks Enric Roche for Demonstrating the Piston Effect
-
Nov 15, 2025, 15:41Thrombectomy Rates Rise 700% Nationwide
-
Nov 15, 2025, 15:41Emmanuel J. Favaloro: Transitioning Patients from DOACs to Heparin
-
Nov 15, 2025, 15:40Bruno Lima: I Owe a Lot of My Career to Dr. Brad Maron